Please Scroll Down to See Forums Below
napsgear
genezapharmateuticals
domestic-supply US-PHARMACIES UGL OZ
Raptor Labs UGFREAK OxygenPharm
napsgeargenezapharmateuticals domestic-supplyUS-PHARMACIES UGL OZUGFREAKRaptor LabsOxygenPharm

aromasin or arimidex

  • Thread starter Thread starter cbeaks
  • Start date Start date
C

cbeaks

Guest
If cost is not a factor, which would you choose? From what I understand, aromasin seems to be more effective but it seems like I hardly ever hear of anyone using it.
 
Lowest said:
Aromasin definitely. Better anti-e and doesn't have the negative lipid effects.

thanks lowest. That's what I have been using
 
I have 25mg tabs. I heard that 50 mg tabs are also made. Is this true?
 
I thought 25mg was supposed to eliminate something like 95% of the estrogen in your body...what could someone do with 50mg?
 
iam curious on how aromasin does not affect lipid profiles when it lowers estrogen to nil just like letrozole and arimidex anyone have asny opinions on this
 
I prefer Arimidex and Famera over aromasin, after experiences w/ both I avoid the aromasin - here in Mexico Aromasin is cheap but again what isn't lol

X
 
can anyone post some studies that prove aromasin does not affect lipid profiles iam pretty doubtful about this .i believe the reason why arimidex and letrozole affect lipid profiles ids due to the lowering of estrogen now if iam wrong please correct me ok so if aromasin is stronger then arim and let how does it not affect lipids justa thought anyone have any opinions on this
 
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.

Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R.

Jules Bordet Institute, Brussels, Belgium.

BACKGROUND: The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients. PATIENTS AND METHODS: The EORTC trial 10951 randomised 122 postmenopausal breast cancer patients to exemestane (E) 25 mg (n = 62) or tamoxifen (T) 20 mg (n = 60) once daily as a first-line treatment in the metastatic setting. Exemestane showed promising results in all the primary efficacy end points of the trial (response rate, clinical benefit rate and response duration), and it was well tolerated with low incidence of serious toxicity. As a secondary end point of this phase II trial, serum triglycerides (TRG), high-density lipoprotein cholesterol (HDL), total cholesterol (TC), lipoprotein a (Lip a), and apolipoproteins (Apo) B and A1 were measured at baseline and while on therapy (at 8, 24 and 48 weeks) to assess the impact of exemestane and tamoxifen on serum lipid profiles. Of the 122 randomised patients, those who had baseline and at least one other lipid assessment are included in the present analysis. The patients who received concomitant drugs that could affect lipid profile are included only if these drugs were administered throughout the study treatment. Increase or decrease in lipid parameters within 20% of baseline were considered as non-significant and thus unchanged. RESULTS: Seventy-two patients (36 in both arms) were included in the statistical analysis. The majority of patients had abnormal TC and normal TRG, HDL, Apo A1, Apo B and Lip a levels at baseline. Neither exemestane nor tamoxifen had adverse effects on TC, HDL, Apo A1, Apo B or Lip a levels at 8, 24 and 48 weeks of treatment. Exemestane and tamoxifen had opposite effects on TRG levels: exemestane lowered while tamoxifen increased TRG levels over time. There were too few patients with normal baseline TC and abnormal TRG, HDL, Apo A1, Apo B and Lip a levels to allow for assessment of E's impact on these subsets. The atherogenic risk determined by Apo A1:Apo B and TC:HDL ratios remained unchanged throughout the treatment period in both the E and T arms. CONCLUSIONS: Overall, exemestane has no detrimental effect on cholesterol levels and the atherogenic indices, which are well-known risk factors for coronary artery disease. In addition, it has a beneficial effect on TRG levels. These data, coupled with E's excellent efficacy and tolerability, support further exploration of its potential in the metastatic, adjuvant and chemopreventive setting.
 
thanks poantrex i stil do not understand how id does not affect cholestorol while lowering estrogen levels oh welll guess i gota try and see how it works
 
Top Bottom